Please login to the form below

Not currently logged in
Email:
Password:

Earnings down for Cephalon

US-based biopharmaceutical firm Cephalon has recorded a 14 per cent decrease in net profit despite rising sales over the second quarter of 2011

US-based biopharmaceutical firm Cephalon has recorded a 14 per cent decrease in net profit despite rising sales over the second quarter of 2011.

The company had a net profit $142.6m compared to $165.3m in 2010.

Sales increased by 2 per cent however, with total revenue reported as $730.1m.

The company's oncology division had a particular impact on the company's performance, with sales up 22 per cent to $158.8m. This was helped by significant sales of chronic lymphocytic leukaemia treatment Treanda (bendamustine hydrochloride).

Cephalon is currently in the middle of an acquisition by Teva Pharmaceutical. In May, 2010, the companies entered into an agreement where Teva would acquire all outstanding shares in Cephalon for $81.50 per share in cash, a total value of around $6.8bn

In the quarterly report, Kevin Buchi, CEO, Cephalon, said: "We continue to work with both US and European authorities to obtain all necessary regulatory approvals in order to close the transaction with Teva."

3rd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics